Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
First Test Concor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| First Test Concor (Fasted), Then Reference Concor (Fasted) | EXPERIMENTAL | Participants will receive a single oral dose of Test Concor tablet on Day 1 in treatment period 1 followed by single oral dose of reference Concor tablet on Day 8 in treatment period 2 under fasted condition. There will be separate washout period of 7 days between each treatment period. |
| First Reference Concor (Fasted), Then Test Concor (Fasted) | EXPERIMENTAL | Participants will receive a single oral dose of Reference Concor tablet on Day 1 in treatment period 1 followed by single oral dose of Test Concor tablet on day 8 in treatment period 2 under fasted condition. There will be separate washout period of 7 days between each treatment period. |
| First Test Concor (Fed), Then Reference Concor (Fed) | EXPERIMENTAL | Participants will receive a single oral dose of Test Concor tablet on Day 1 in treatment period 1 followed by a single oral dose of Reference Concor tablet on Day 8 in treatment period 2 under fed condition. There will be separate washout period of 7 days between each treatment period. |
| First Reference Concor (Fed), Then Test Concor (Fed) | EXPERIMENTAL | Participants will receive a single oral dose of Reference Concor tablet on Day 1 in treatment period 1 followed by a single oral dose of Test Concor tablet on Day 8 in treatment period 2 under fed condition. There will be separate washout period of 7 days between each treatment period. |
| Name | Type | Description |
|---|---|---|
| First Test Concor (Fasted) | DRUG | Participants will receive single oral dose of Test Concor tablet under fasted or fed condition. |
| First Reference Concor (Fasted) | DRUG | Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition |
| First Test Concor (Fed) | DRUG | Participants will receive single oral dose of Test Concor tablet under fasted or fed condition. |
| First Reference Concor (Fed) | DRUG | Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition. |
Inclusion Criteria: * Participants are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests and cardiac monitoring * Participant must have a body weight within 50-90 kilogram (kg) and body mass index (BMI) within the range 19-26 kilo...
Concor is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed bioequivalence study in Chinese participants. The drug is being developed by Merck KGaA.
Concor is being developed by Merck KGaA, a company traded under the ticker MKGAF. The drug is currently in Phase 1 clinical development, with one completed trial in healthy volunteers.
Concor is in Phase 1 clinical development. It has one completed trial, a bioequivalence study in healthy Chinese participants. The drug is investigational and has not been approved for any indication.
Concor has one completed clinical trial, NCT05930808, a Phase 1 bioequivalence study in healthy Chinese participants. The study enrolled 46 participants and was conducted in China.
Concor is the drug name used in clinical development. The completed trial, NCT05930808, is titled 'Concor® Bioequivalence Study in Chinese Participants (Darmstadt-Nantong).' No alternative names have been reported for this drug.